1887

Journal of Medical Microbiology logo

Volume 69, Issue 1

Engineering of an Iranian strain producing inactive pertussis toxin Free

Abstract

Differences between the genomic and virulence profile of circulating strains and vaccine strains are considered as one of the important reasons for the resurgence of whooping cough (pertussis) in the world. Genetically inactivated is one of the new strategies to generate live-attenuated vaccines against whooping cough.

The aim of this study was to construct a strain based on a predominant profile of circulating Iranian isolates that produces inactivated pertussis toxin (PTX).

The strain BPIP91 with predominant genomic and virulence pattern was selected from the biobank of the Pasteur Institute of Iran. A BPIP91 derivative with R9K and E129G alterations in the S1 subunit of PTX (S1mBPIP91) was constructed by the site-directed mutagenesis and homologous recombination. Genetic stability and antigen expression of S1mBPIP91 were tested by serially passages and immunoblot analyses, respectively. The reduction in toxicity of S1mBPIP91 was determined by Chinese hamster ovary (CHO) cell clustering.

All constructs and S1mBPIP91 were confirmed via restriction enzyme analysis and DNA sequencing. The engineered mutations in S1mBPIP91 were stable after 20 serial passages. The production of virulence factors was also confirmed in S1mBPIP91. The CHO cell-clustering test demonstrated the reduction in PTX toxicity in S1mBPIP91.

A of the predominant genomic and virulence lineage in Iran was successfully engineered to produce inactive PTX. This attenuated strain will be useful to further studies to develop both whole cell and acellular pertussis vaccines.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): Bordetella pertussis , homologous recombination , S1 subunit and vaccine
© 2020 The Authors
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001114
2020-01-01
2024-04-26
Loading full text...

Full text loading...

/deliver/fulltext/jmm/69/1/111.html?itemId=/content/journal/jmm/10.1099/jmm.0.001114&mimeType=html&fmt=ahah

References

  1. Yeung KHT, Duclos P, Nelson EAS, Hutubessy RCW. An update of the global burden of pertussis in children younger than 5 years: a modelling study. Lancet Infect Dis 2017; 17:974–980 [View Article]
     [Google Scholar]
  2. Ausiello CM, Cassone A. Acellular pertussis vaccines and pertussis resurgence: revise or replace?. MBio 2014; 5:e01339–01314 [View Article]
     [Google Scholar]
  3. Locht C. Will we have new pertussis vaccines?. Vaccine 2018; 36:5460–5469 [View Article]
     [Google Scholar]
  4. Kilgore PE, Salim AM, Zervos MJ, Schmitt H-J. Pertussis: microbiology, disease, treatment, and prevention. Clin Microbiol Rev 2016; 29:449–486 [View Article]
     [Google Scholar]
  5. World Health Organization Pertussis vaccines: who position paper. Wkly Epidemiol Rec 2015; 35:433–460
     [Google Scholar]
  6. Mooi FR, van Loo IHM, King A. Adaptation of Bordetella pertussis to Vaccination: a cause for its reemergence?. Emerg Infect Dis 2001; 7:526–528 [View Article]
     [Google Scholar]
  7. Mooi FR. Bordetella pertussis and vaccination: the persistence of a genetically monomorphic pathogen. Infection, Genetics and Evolution 2010; 10:36–49 [View Article]
     [Google Scholar]
  8. Bart MJ, van Gent M, van der Heide HGJ, Boekhorst J, Hermans P et al. Comparative genomics of prevaccination and modern Bordetella pertussis strains. BMC Genomics 2010; 11:627–636 [View Article]
     [Google Scholar]
  9. King AJ, van Gorkom T, van der Heide HGJ, Advani A, van der Lee S. Changes in the genomic content of circulating Bordetella pertussis strains isolated from the Netherlands, Sweden, Japan and Australia: adaptive evolution or drift?. BMC Genomics 2010; 11:64–78 [View Article]
     [Google Scholar]
  10. Kallonen T, He Q. Bordetella pertussis strain variation and evolution postvaccination. Expert Rev Vaccines 2009; 8:863–875 [View Article]
     [Google Scholar]
  11. Vr B, Hegerle N, Strati F, Njamkepo E, Guiso N. New data on vaccine antigen deficient Bordetella pertussis isolates. Vaccines 2015; 3:751–770
     [Google Scholar]
  12. Williamson YM, Moura H, Whitmon J, Woolfitt AR, Schieltz DM et al. A Proteomic Characterization of Bordetella pertussis clinical isolates associated with a california state pertussis outbreak. Int J Proteomics 2015; 2015:1–12 [View Article]
     [Google Scholar]
  13. Bottero D, Gaillard ME, Fingermann M, Weltman G, Fernández J et al. Pulsed-field gel electrophoresis, pertactin, pertussis toxin S1 subunit polymorphisms, and surfaceome analysis of vaccine and clinical Bordetella pertussis strains. Clin Vaccine Immunol 2007; 14:1490–1498 [View Article]
     [Google Scholar]
  14. Mills KHG, Ross PJ, Allen AC, Wilk MM. Do we need a new vaccine to control the re-emergence of pertussis?. Trends Microbiol 2014; 22:49–52 [View Article]
     [Google Scholar]
  15. Borisova O, Kombarova SY, Zakharova NS, van Gent M, Aleshkin VA et al. Antigenic divergence between Bordetella pertussis clinical isolates from Moscow, Russia, and vaccine strains. Clin Vaccine Immunol 2007; 14:234–238 [View Article]
     [Google Scholar]
  16. World Health Organization Who technical report series no 941 Annex 6. Recommendations for whole-cell pertussis vaccine 2007; 6:301–333
     [Google Scholar]
  17. Roberts R, Moreno G, Bottero D, Gaillard ME, Fingermann M et al. Outer membrane vesicles as acellular vaccine against pertussis. Vaccine 2008; 26:4639–4646 [View Article]
     [Google Scholar]
  18. Bottero D, Gaillard ME, Zurita E, Moreno G, Martinez DS et al. Characterization of the immune response induced by pertussis OMVs-based vaccine. Vaccine 2016; 34:3303–3309 [View Article]
     [Google Scholar]
  19. Elahi S, Van Kessel J, Kiros TG, Strom S, Hayakawa Y et al. C-Di-Gmp enhances protective innate immunity in a murine model of pertussis. PLoS One 2014; 9:e109778 [View Article]
     [Google Scholar]
  20. Dunne A, Mielke LA, Allen AC, Sutton CE, Higgs R et al. A novel TLR2 agonist from Bordetella pertussis is a potent adjuvant that promotes protective immunity with an acellular pertussis vaccine. Mucosal Immunol 2015; 8:607–617 [View Article]
     [Google Scholar]
  21. Cheung GYC, Xing D, Prior S, Corbel MJ, Parton R et al. Effect of different forms of adenylate cyclase toxin of Bordetella pertussis on protection afforded by an acellular pertussis vaccine in a murine model. Infect Immun 2006; 74:6797–6805 [View Article]
     [Google Scholar]
  22. Marr N, Oliver DC, Laurent V, Poolman J, Denoël P et al. Protective activity of the Bordetella pertussis BrkA autotransporter in the murine lung colonization model. Vaccine 2008; 26:4306–4311 [View Article]
     [Google Scholar]
  23. Mielcarek N, Debrie A-S, Raze D, Bertout J, Rouanet C et al. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog 2006; 2:e65 [View Article]
     [Google Scholar]
  24. Thorstensson R, Trollfors B, Al-Tawil N, Jahnmatz M, Bergström J et al. A phase I clinical study of a live attenuated Bordetella pertussis vaccine--BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers. PLoS One 2014; 9:e83449 [View Article]
     [Google Scholar]
  25. Locht C, Coutte L, Mielcarek N. The Ins and outs of pertussis toxin. Febs J 2011; 278:4668–4682 [View Article]
     [Google Scholar]
  26. Pittman M. Pertussis toxin: the cause of the harmful effects and prolonged immunity of whooping cough. A hypothesis. Clinical Infectious Diseases 1979; 1:401–412 [View Article]
     [Google Scholar]
  27. Locht C, Antoine R. A proposed mechanism of ADP-ribosylation catalyzed by the pertussis toxin S1 subunit. Biochimie 1995; 77:333–340 [View Article]
     [Google Scholar]
  28. Nencioni L, Pizza M, Bugnoli M, De Magistris T, Di Tommaso A et al. Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping cough. Infect Immun 1990; 58:1308–1315
     [Google Scholar]
  29. Pizza M, Covacci A, Bartoloni A, Perugini M, Nencioni L et al. Mutants of pertussis toxin suitable for vaccine development. Science 1989; 246:497–500 [View Article]
     [Google Scholar]
  30. Buasri W, Impoolsup A, Boonchird C, Luengchaichawange A, Prompiboon P et al. Construction of Bordetella pertussis strains with enhanced production of genetically-inactivated Pertussis Toxin and Pertactin by unmarked allelic exchange. BMC Microbiol 2012; 12:61–76 [View Article]
     [Google Scholar]
  31. Loosmore SM, Zealey GR, Boux HA, Cockle SA, Radika K et al. Engineering of genetically detoxified pertussis toxin analogs for development of a recombinant whooping cough vaccine. Infect Immun 1990; 58:3653–3662
     [Google Scholar]
  32. WHO 2019; WHO vaccine-preventable diseases: monitoring system. http://apps.who.int/immunization_monitoring/globalsummary Last updated 15-July-2019
  33. Sadeghpour Heravi F, Nikbin VS, Nakhost Lotfi M, Badiri P, Jannesar Ahmadi N et al. Strain variation and antigenic divergence among Bordetella pertussis circulating strains isolated from patients in Iran. Eur J Clin Microbiol Infect Dis 2018; 37:1893–1900 [View Article]
     [Google Scholar]
  34. Hallander H, Advani A, Riffelmann M, von König CHW, Caro V et al. Bordetella pertussis strains circulating in Europe in 1999 to 2004 as determined by pulsed-field gel electrophoresis. J Clin Microbiol 2007; 45:3257–3262 [View Article]
     [Google Scholar]
  35. Nikbin VS, Keramati M, Noofeli M, Bolourchi N, Shams Nosrati MS et al. Characterization of a predominant Bordetella pertussis strain isolated from Iranian patients. Vaccine Res 2019; 5:52–56
     [Google Scholar]
  36. Stibitz S. Use of conditionally counterselectable suicide vectors for allelic exchange. Methods Enzymol 1994; 235:458–465 [View Article]
     [Google Scholar]
  37. Feunou PF, Ismaili J, Debrie A-S, Huot L, Hot D et al. Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1. Vaccine 2008; 26:5722–5727 [View Article]
     [Google Scholar]
  38. Stainer DW, Scholte MJ. A simple chemically defined medium for the production of phase I Bordetella pertussis . J Gen Microbiol 1970; 63:211–220 [View Article]
     [Google Scholar]
  39. Tsang RSW, Shuel M, Jamieson FB, Drews S, Hoang L et al. Pertactin-negative Bordetella pertussis strains in Canada: characterization of a dozen isolates based on a survey of 224 samples collected in different parts of the country over the last 20 years. Int J Infect Dis 2014; 28:65–69 [View Article]
     [Google Scholar]
  40. Halperin SA, Bortolussi R, Kasina A, Wort AJ. Use of a Chinese hamster ovary cell cytotoxicity assay for the rapid diagnosis of pertussis. J Clin Microbiol 1990; 28:32–38
     [Google Scholar]
  41. Locht C, Mielcarek N. New pertussis vaccination approaches: en route to protect newborns?. FEMS Immunol Med Microbiol 2012; 66:121–133 [View Article]
     [Google Scholar]
  42. Bouchez V, Brun D, Cantinelli T, Dore G, Njamkepo E et al. First report and detailed characterization of B. pertussis isolates not expressing pertussis toxin or pertactin. Vaccine 2009; 27:6034–6041 [View Article]
     [Google Scholar]
  43. Williams MM, Sen K, Weigand MR, Skoff TH, Cunningham VA et al. Bordetella pertussis Strain Lacking Pertactin and Pertussis Toxin. Emerg Infect Dis 2016; 22:319–322 [View Article]
     [Google Scholar]
  44. Guiso N. Bordetella pertussis: why is it still circulating?. J Infect 2014; 68:S119–S124 [View Article]
     [Google Scholar]
  45. Weber C, Boursaux-Eude C, Coralie G, Caro V, Guiso N. Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years. J Clin Microbiol 2001; 39:4396–4403 [View Article]
     [Google Scholar]
  46. Kallonen T, Gröndahl-Yli-Hannuksela K, Elomaa A, Lutyńska A, Fry NK et al. Differences in the genomic content of Bordetella pertussis isolates before and after introduction of pertussis vaccines in four European countries. Infection, Genetics and Evolution 2011; 11:2034–2042 [View Article]
     [Google Scholar]
  47. Munoz JJ, Arai H, Cole RL. Mouse-protecting and histamine-sensitizing activities of pertussigen and fimbrial hemagglutinin from Bordetella pertussis . Infect Immun 1981; 32:243–250
     [Google Scholar]
  48. Nicosia A, Bartoloni A, Perugini M, Rappuoli R. Expression and immunological properties of the five subunits of pertussis toxin. Infect Immun 1987; 55:963–967
     [Google Scholar]
  49. Marsili I, Pizza M, Giovannoni F, Volpini G, Bartalini M et al. Cellular pertussis vaccine containing a Bordetella pertussis strain that produces a nontoxic pertussis toxin molecule. Infect Immun 1992; 60:1150–1155
     [Google Scholar]
  50. Brennan M. A new whooping cough vaccine that may prevent colonization and transmission. Vaccines 2017; 5:43 [View Article]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001114
Loading
Engineering of an Iranian Bordetella pertussis strain producing inactive pertussis toxin
J. Med. Microbiol. 69, 111 (2020); https://doi.org/10.1099/jmm.0.001114
/content/journal/jmm/10.1099/jmm.0.001114
/content/journal/jmm/10.1099/jmm.0.001114
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error